HOLX News and Press, Hologic Inc. From 01/31/23

Summary Hologic was a beneficiary of the pandemic, catching a strong bid across that period. With its FY22 numbers, investors have re-rated the stock back to the upside. We believe a further re-rating is warranted, and that the stock deserves a high P/E based on its return on capita...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

The following slide deck was published by Hologic, Inc. in conjunction with this event. For further details see: Hologic (HOLX) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow

Hologic ( NASDAQ: HOLX ) expects to report Q1 total revenues of ~$1.074B, a decrease of 27.0% compared to the prior year period, or 25.1% in constant currency vs. consensus of $970.3M. The preliminary results are higher than the company's most recent revenue guidance range of $940...

– Revenue of $1,074.2 Million Exceeds Guidance – – 15.8% Organic Constant Currency Growth in Diagnostics ex-COVID – – 24.5% Organic Constant Currency Growth in Molecular Diagnostics ex-COVID – – 14.7% Organic Constant Currency Growth in...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2023 on Wednesday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. ...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time. The presentation and Q&A session will be webcast live and may be accessed through a link on the Inv...

Hologic, Inc. (Nasdaq: HOLX) announced today that Stacey D. Stewart has been elected to the Company’s Board of Directors, effective January 2, 2023. Ms. Stewart was also appointed to the Audit and Finance Committee effective January 2, 2023. This press release features multimedia. View...

The Breast Cancer Index Test Is the First Biomarker to Predict Treatment Benefit in the SOFT Trial Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients wit...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...